Your dog is probably on Prozac. What that says about the U.S. mental health crisis

Pet psychiatry mirrors human trends in several ways, and vets across the country say they are writing more anti-anxiety prescriptions.

April 6, 2024 Check out STAT+

Sponsored By

It's National Public Health Week — get three months of STAT+ for $20, and you'll receive access to our deepest stories, exclusives, and investigations related to biopharma, policy and politics, the life sciences, and health tech.

Vadim Ghirada/AP Your dog is probably on Prozac. Experts say that says more about the American mental health crisis than pets Prozac prescriptions for dogs are on the rise, veterinarians across the country acknowledge, along with a myriad of cheaper generic mood stabilizers sold for humans but applied to pets' separation anxiety, socialization fears, biting habits, or other problematic behavior. Read more. By Sarah Owermohle

---

---

Molly Ferguson for STAT DNA test that predicts opioid addiction should be pulled off the market, critics urge the FDA Last December, the FDA approved a DNA test to help guide physicians' opioid-prescribing decisions. But as the test maker prepares to roll it out this week, prominent geneticists, public health researchers, and experts in addiction and device regulation are calling on the FDA to reverse itself and take AvertD off the market, saying that the test lacks a firm scientific foundation. Read more. By Megan Molteni STAT This AI company scans penis pictures for STIs. Its unproven tech is in an FDA gray zone Artificial intelligence is already assessing decay in your teeth, abnormalities in your heart rhythm, and suspicious spots on your skin. Now, at least one company is betting that you will let it take a look at your penis. HeHealth claims that its AI model can detect a range of sexually transmitted infections from a single snapshot of one's genitals. Read more. By Lizzy Lawrence More great reads from STAT this week What we know about H5N1 bird flu in cows — and the risk to humans Matt & Adam's Take: Amylyx did the right thing by withdrawing its ALS drug. That's rare and worthy of praise Scientists uncover potential path to treating deadly childhood tumor Opinion: I saw the promise of diversity efforts in health care. A moment later I saw its critical gaps Critics say U.K. decision on ALS drug could have 'chilling effect' on access to new genetic medicines

---

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Weekend Reads? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser